Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAE1 | Q13564 | 6/20 | 0.40 |
| ▸ | UBA3 | Q8TBC4 | 5/20 | 0.40 |
| ▸ | KLKB1 | P03952 | 4/20 | 0.35 |
| ▸ | KLK1 | P06870 | 4/20 | 0.35 |
| ▸ | ATG7 | O95352 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 3/20 | 0.31 |
| ▸ | GRK5 | P34947 | 1/20 | 0.31 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.31 |
| ▸ | UBA6 | A0AVT1 | 1/20 | 0.31 |
| ▸ | NEDD8 | Q15843 | 1/20 | 0.31 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.31 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.31 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17889881 | 0.92 | NAE1 (0.39) | NAE1UBA3KLKB1KLK1ATG7 | |
| SCHEMBL1794585 | 0.86 | POLB (0.37) | KLKB1KLK1 | |
| SCHEMBL1795226 | 0.85 | NAE1 (0.47) | NAE1UBA3ATG7CA2 | |
| SCHEMBL12566443 | 0.79 | KLKB1 (0.40) | NAE1UBA3KLKB1KLK1CA2 | |
| SCHEMBL17889883 | 0.78 | POLB (0.35) | KLKB1KLK1 | |
| SCHEMBL1797922 | 0.76 | CA2 (0.41) | NAE1UBA3ATG7CA2GRK5 | |
| SCHEMBL14430991 | 0.72 | ATG7 (0.53) | NAE1UBA3ATG7CA2GRK5 | |
| SCHEMBL1797778 | 0.72 | TOP2A (0.33) | — | |
| SCHEMBL17889847 | 0.72 | TOP2A (0.33) | — | |
| SCHEMBL12856900 | 0.71 | NPC1 (0.52) | DNPH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210070798-A1 | Inhibitors of E1 activating enzymes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-11 | — | — | US | disclosed |
| US-20180086785-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | MILLENNIUM PHARMACEUTICALS, INC. | 2018-03-29 | — | — | US | disclosed |
| EP-1848718-B1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARM INC (US) | 2012-08-01 | — | — | EP | disclosed |
| US-20110136834-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | US | disclosed |
| US-7951810-B2 | Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| US-20060189636-A1 | Inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086785-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | TYMP, TYMS, PPA1 | NAE1 257/4885UBA3 235/4885KLKB1 3193/4885 |
| US-20110136834-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | ECE1, RNASE1, RCE1 | NAE1 41/4885UBA3 12/4885KLKB1 1669/4885 |
| US-20210070798-A1 | Inhibitors of E1 activating enzymes | ECE1, RNASE1, RCE1 | NAE1 41/4885UBA3 12/4885KLKB1 1669/4885 |
| US-20060189636-A1 | Inhibitors of E1 activating enzymes | ECE1, RNASE1, RCE1 | NAE1 41/4885UBA3 12/4885KLKB1 1669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.